Signals, Powered By EquityPandit
A long term strategic manufacturing agreement has been signed by Sun Pharma and Samsung Biologics for Tildrakizumab which is used in treating psoriasis.
The company has said in a BSE filing that “The agreement was entered into by Sun Pharma’s wholly owned subsidiary and Samsung BioLogics…Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p 19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.”
The approximate value of the contract will be USD 55.5 million, Sun Pharma said.
